A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).
B. Han,Q. Xiu,Y. Luo,C. Bai,S. Guo,W. Liu,Z. Zhuang,Y. Zhang,J. Zhou,X. Jin
DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.7527
IF: 45.3
2010-01-01
Journal of Clinical Oncology
Abstract:7527 Background: Endostatin is one of the most effective inhibitors of tumor angiogenesis. Clinical studies have shown that chemotherapy combined with endostatin could improve response rate and the survival of patients. Methods: Chemotherapy-naive consenting patients with stage IIIB/IV NSCLC, performance status (PS) 0-2, aged 18-75 years and normal organ function, who had stable disease (SD) or above after receiving a first cycle TC, were enrolled in this study. Eligible patients were randomly assigned to the endostatin treatment group (TC + endostatin. T:175 mg/m2 d1, C:AUC = 5 d1, endostatin:7.5 mg/m2, d8-d21,q3w) or the control group (TC + placebo), and received three cycles of chemotherapy. The primary endpoint was time to progression (TTP); secondary endpoints were objective response rate (ORR), progression-free survival (PFS), clinical benefit rate (CBR), and safety. Results: From Jul 2007 to Aug 2008, 126 patients were randomized 1: 1 to the endostatin treatment group (Arm E) and the control group (Arm C).The ORR was 39.3% in Arm E and 23.0% in Arm C. The ORR of patients treated with endostatin plus chemotherapy increased 16.3% over those treated only with chemotherapy (p = 0.078). The CBR was 90.2% in Arm E and 67.2% in Arm C, and there was a significant difference between the two groups (p = 0.004). The median TTP in Arm E and Arm C were 7.1 and 6.3 months, respectively. The 24-week hazard ratio (HR) was 0.416 (95% confidence interval: 0.209-0.827, p = 0.012). The 16-week rates of PFS in Arm E and Arm C were 90% and 75%, respectively (p = 0.033). The 24- week rates of PFS in Arm E and Arm C were 78% and 59%, respectively (p = 0.017). Survival profile need further follow-up. There was no significant difference in the incidence rates of adverse events and serious adverse events between the two groups. Conclusions: In previously untreated advanced NSCLC, treatments with TC plus endostatin could significantly improve the 16-week and 24-week rates of PFS, ORR and CBR. The safety profile was similar. Chemotherapy combined with endostatin might play a role in the improvement of response rate and the survival of patients with advanced NSCLC. No significant financial relationships to disclose.